Back
  • Publish Date: Posted 6 months ago
  • Author: Sarah Seaford
​🚀 Exciting news from the biotech frontier!

Great to see that T-Therapeutics Ltd, a UK-based biotech company pioneering next-generation T-Cell Receptor (TCR) therapeutics for cancer and autoimmune diseases, has expanded its Series A financing, bringing the total raised to US $91 million!

✅ The additional funding will propel their pipeline of first-in-class TCR-CD3 bispecifics across both oncology and autoimmune disease indications.
✅ Their lead oncology asset targets a pan-tumour driver, applicable across multiple solid tumour types - an approach with broad potential impact.
✅ Their lead immunology programme is a pan-autoimmune bispecific engineered for precision immune reset, selectively depleting pathogenic immune cells rather than broad suppression.

Kudos to the T-Therapeutics team for taking bold steps toward translating deep science into transformative medicines. I look forward to tracking their progress as they advance toward the clinic. 👏

https://lnkd.in/en9JETH9